IRIS Institutional Research Information System - OPENBS Open Archive UniBS

Cosentini, Deborah
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.898
AS - Asia 2.582
EU - Europa 2.088
SA - Sud America 444
AF - Africa 60
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 1
Totale 10.077
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.800
SG - Singapore 1.047
CN - Cina 658
IT - Italia 490
BR - Brasile 355
PL - Polonia 347
FI - Finlandia 260
HK - Hong Kong 252
DE - Germania 242
VN - Vietnam 219
GB - Regno Unito 111
UA - Ucraina 111
FR - Francia 110
TR - Turchia 89
RU - Federazione Russa 86
IE - Irlanda 82
IN - India 76
CA - Canada 56
SE - Svezia 50
BD - Bangladesh 49
ID - Indonesia 41
CZ - Repubblica Ceca 40
AR - Argentina 38
JP - Giappone 36
NL - Olanda 32
ES - Italia 31
MX - Messico 27
BE - Belgio 26
ZA - Sudafrica 23
IQ - Iraq 21
AT - Austria 16
CH - Svizzera 12
EC - Ecuador 12
CL - Cile 11
PK - Pakistan 11
SA - Arabia Saudita 10
LT - Lituania 9
MA - Marocco 9
PT - Portogallo 9
UZ - Uzbekistan 9
DZ - Algeria 8
PH - Filippine 8
AE - Emirati Arabi Uniti 7
JO - Giordania 6
VE - Venezuela 6
AL - Albania 5
AZ - Azerbaigian 5
BG - Bulgaria 5
CO - Colombia 5
CR - Costa Rica 5
KE - Kenya 5
LB - Libano 5
PY - Paraguay 5
EG - Egitto 4
ET - Etiopia 4
JM - Giamaica 4
NP - Nepal 4
PA - Panama 4
PE - Perù 4
TH - Thailandia 4
TW - Taiwan 4
AU - Australia 3
GY - Guiana 3
KG - Kirghizistan 3
KZ - Kazakistan 3
LV - Lettonia 3
OM - Oman 3
RO - Romania 3
BO - Bolivia 2
EE - Estonia 2
IL - Israele 2
PS - Palestinian Territory 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
TN - Tunisia 2
UY - Uruguay 2
ZW - Zimbabwe 2
AO - Angola 1
BB - Barbados 1
BH - Bahrain 1
CY - Cipro 1
EU - Europa 1
FK - Isole Falkland (Malvinas) 1
HN - Honduras 1
IR - Iran 1
KR - Corea 1
LA - Repubblica Popolare Democratica del Laos 1
MD - Moldavia 1
MK - Macedonia 1
MU - Mauritius 1
MY - Malesia 1
NZ - Nuova Zelanda 1
QA - Qatar 1
SY - Repubblica araba siriana 1
TG - Togo 1
Totale 10.077
Salva come PNG Salva come JPEG
Città #
Singapore 544
Ashburn 491
Dallas 377
Warsaw 341
San Jose 294
Fairfield 275
Hong Kong 251
Chicago 239
Los Angeles 195
Helsinki 191
New York 168
Chandler 157
Beijing 152
Seattle 124
The Dalles 116
Houston 115
Woodbridge 111
Salt Lake City 100
Wilmington 98
Munich 92
Council Bluffs 89
Cambridge 79
Jacksonville 77
Istanbul 69
Princeton 69
Brescia 66
Ho Chi Minh City 61
Lauterbourg 61
Buffalo 60
Secaucus 60
Milan 53
Tampa 51
Dublin 48
Turku 48
Elk Grove Village 47
Boardman 44
Ann Arbor 43
Shanghai 43
Moscow 42
Hanoi 40
Redondo Beach 38
Jakarta 37
Dalmine 36
Santa Clara 34
Brno 32
Orem 31
West Jordan 30
Des Moines 28
Dong Ket 28
Rome 27
Sterling 27
São Paulo 27
Bergamo 26
Brussels 26
London 25
San Francisco 25
Menlo Park 22
Brooklyn 20
Dearborn 20
Lancaster 20
Montreal 20
Naples 20
Poplar 20
Romola 20
Stockholm 20
Nuremberg 18
Rio de Janeiro 18
Chennai 17
Frankfurt am Main 17
Johannesburg 17
Lappeenranta 17
Nanjing 17
Tokyo 17
Atlanta 16
Mumbai 16
Phoenix 16
Boston 14
Dulles 14
Pune 14
Denver 13
Haiphong 13
San Diego 13
Amsterdam 12
Washington 12
Guangzhou 11
Miami 11
Tianjin 11
Toronto 11
Biên Hòa 10
Detroit 10
New Delhi 10
Paris 10
Ankara 9
Changsha 9
Da Nang 9
Gumyojicho 9
Kansas City 9
Kyiv 9
Manchester 9
Nanchang 9
Totale 6.687
Salva come PNG Salva come JPEG
Nome #
Cytotoxic Effect of Progesterone, Tamoxifen and Their Combination in Experimental Cell Models of Human Adrenocortical Cancer 787
Efficacy of the EDP-M Scheme Plus Adjunctive Surgery in the Management of Patients with Advanced Adrenocortical Carcinoma: The Brescia Experience. 378
Eight‐week interval in flushing and locking port‐a‐cath in cancer patients: A single‐institution experience and systematic review 252
Are we failing in treatment of adrenocortical carcinoma? Lights and shadows of molecular signatures 251
In vitro cytotoxicity of cabazitaxel in adrenocortical carcinoma cell lines and human adrenocortical carcinoma primary cell cultures☆ 247
Hepatoprotective effect of N-acetylcysteine in trabectedin-induced liver toxicity in patients with advanced soft tissue sarcoma 246
IN VITRO ANTITUMOR ACTIVITY OF PROGESTERONE IN HUMAN ADRENOCORTICAL CARCINOMA 226
Cytotoxic Effect of Trabectedin In Human Adrenocortical Carcinoma Cell Lines and Primary Cells 221
Immunotherapy failure in adrenocortical cancer: where next? 220
Molecular Drivers of Potential Immunotherapy Failure in Adrenocortical Carcinoma. 197
Adrenocortical Carcinoma and CT Assessment of Therapy Response: The Value of Combining Multiple Criteria 197
The guanine nucleotide exchange factor VAV2 as a new prognostic parameter in adrenocortical carcinoma 190
Decision-making for adrenocortical carcinoma: surgical, systemic, and endocrine management options 187
Sacituzumab govitecan and radiotherapy in metastatic, triple-negative, and BRCA-mutant breast cancer patient with active brain metastases: A case report 179
Antineoplastic Activity of Artemisinin in Adrenocortical Carcinoma 178
Activity and safety of temozolomide in advanced adrenocortical carcinoma patients 177
Different management of adrenocortical carcinoma in children compared to adults: is it time to share guidelines? 169
Cost-effectiveness of model-based eligibility for lung cancer screening in the routine clinical practice 163
A Comprehensive Investigation of Steroidogenic Signaling in Classical and New Experimental Cell Models of Adrenocortical Carcinoma 145
Changes in eating habits and food preferences in breast cancer patients undergoing adjuvant chemotherapy 143
Ribociclib Cytotoxicity Alone Or Combined With Progesterone And/Or Mitotane In In Vitro Adrenocortical Carcinoma Cells 138
Efficacy of the DigniCap System in preventing chemotherapy-induced alopecia in breast cancer patients is not related to patient characteristics or side effects of the device 134
Gastrointestinal Toxicity of Antibody Drug Conjugates (ADCs) in Metastatic Breast Cancer: A Pooled Analysis 131
Treatment with 90Y/177Lu DOTATOC in patients with metastatic adrenocortical carcinoma expressing somatostatin receptors 130
Accurate Triage of Oncological Patients for Safely Continuing Cancer Therapy During the SARS-CoV-2 Pandemic 130
Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study 126
Case Report: Exceptional Response to Second Line Temozolomide Therapy in a Patient With Metastatic Adrenocortical Carcinoma 123
Ovarian Strumal Carcinoid: Case Report, Systematic Literature Review and Pooled Analysis 122
Advances in adrenocortical carcinoma pharmacotherapy: what is the current state of the art? 122
Preclinical Evidence of Progesterone as a New Pharmacological Strategy in Human Adrenocortical Carcinoma Cell Lines 120
Assessment of DXA derived bone quality indexes and bone geometry parameters in early breast cancer patients: A single center cross-sectional study 117
Transformation of prostate adenocarcinoma into small-cell neuroendocrine cancer under androgen deprivation therapy: Much is achieved but more information is needed 117
Androgen serum levels in male patients with adrenocortical carcinoma given mitotane therapy: A single center retrospective longitudinal study 116
Estrogen-Like Effect of Mitotane Explained by Its Agonist Activity on Estrogen Receptor-α 115
Changes in body composition in early breast cancer patients treated with aromatase inhibitors 113
Microvascular Structural Alterations in Cancer Patients Treated With Antiangiogenic Drugs 113
Supportive therapies in patients with advanced adrenocortical carcinoma submitted to standard EDP-M regimen 112
Adverse skeletal related events in patients with bone-metastatic pheochromocytoma/paraganglioma 110
Clinical Prognostic Factors in Patients With Metastatic Adrenocortical Carcinoma Treated With Second Line Gemcitabine Plus Capecitabine Chemotherapy 109
Trabectedin impairs invasiveness and metastasis in adrenocortical carcinoma preclinical models 107
Feasibility and Activity of Megestrol Acetate in Addition to Etoposide, Doxorubicin, Cisplatin, and Mitotane as First-Line Therapy in Patients with Metastatic/Unresectable Adrenocortical Carcinoma with Low Performance Status 107
Outcome of brain metastases from adrenocortical carcinoma: a pooled analysis 105
Taste Alterations Do Not Affect Change in Food Habits and Body Weight in Breast Cancer Patients 104
The long and winding road to effective immunotherapy in patients with adrenocortical carcinoma 103
Is weight gain preventable in women with early breast cancer undergoing chemotherapy? A real-world study on dietary pattern, physical activity, and body weight before and after chemotherapy 102
Correction to: A Comprehensive Investigation of Steroidogenic Signaling in Classical and New Experimental Cell Models of Adrenocortical Carcinoma (Cells, (2022), 11, 9, (1439), 10.3390/cells11091439) 101
Fat Body Mass and Vertebral Fracture Progression in Women With Breast Cancer 100
Denosumab improves trabecular bone score in relationship with decrease in fracture risk of women exposed to aromatase inhibitors 99
Letter to the editor from Berruti et al: "Cytoreductive Surgery of the Primary Tumor in Metastatic Adrenocortical Carcinoma: Impact on Patients' Survival" 97
Body composition in early breast cancer patients treated with adjuvant aromatase inhibitors: Does dietary counseling matter? 95
Regorafenib-related erythrocytosis in metastatic extra-gastrointestinal stromal tumor: a case report 94
Bone-active drugs in premenopausal women with breast cancer under hormone-deprivation therapies 94
Immune-related adverse events as potential surrogates of immune checkpoint inhibitors’ efficacy: a systematic review and meta-analysis of randomized studies 92
Frequency and outcome of SARS-CoV-2 infection in patients with adrenocortical carcinoma followed at a reference center in Italy 90
Phase II study of cabazitaxel as second-third line treatment in patients with metastatic adrenocortical carcinoma 89
Taste alterations during neo/adjuvant chemotherapy and subsequent follow-up in breast cancer patients: a prospective single-center clinical study 88
Correction: Denosumab improves trabecular bone score in relationship with decrease in fracture risk of women exposed to aromatase inhibitors 87
Maintenance of androgen deprivation therapy or testosterone supplementation in the management of castration-resistant prostate cancer: that is the question 87
Sleep disturbances and restless legs syndrome in postmenopausal women with early breast cancer given adjuvant aromatase inhibitor therapy 87
Prediction of vertebral fractures in cancer patients undergoing hormone deprivation therapies: Reliability of who fracture risk assessment tool (frax) and bone mineral density in real-life clinical practice 82
Adjuvant denosumab for early breast cancer-Evidence and controversy 81
Role of Body Composition in the Prediction of Skeletal Fragility Induced by Hormone Deprivation Therapies in Cancer Patients 80
The Evolving Treatment Landscape of Medullary Thyroid Cancer 79
Progression of vertebral fractures in patients with adrenocortical carcinoma undergoing mitotane therapy 79
Is it time to tailor treatments in androgen receptor positive salivary gland cancers? 78
Germline NGS targeted analysis in adult patients with sporadic adrenocortical carcinoma 69
S-GRAS score for prognostic classification of adrenocortical carcinoma: an international, multicenter ENSAT study 69
Real-World Effectiveness of Denosumab and Bisphosphonates on Risk of Vertebral Fractures in Women with Breast Cancer Undergoing Treatment with Aromatase Inhibitors 69
The Value of Local Therapies in Advanced Adrenocortical Carcinoma 67
Real-world use of multigene signatures in early breast cancer: differences to clinical trials 59
Multigene signatures for early breast cancer in clinical practice: A report of the Lombardy genomic assays for breast cancer working group 58
Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial 57
Molecular genotyping of adrenocortical carcinoma: A systematic analysis of published literature 2019-2021 55
null 51
Letter re: Impact of EDP-M on survival of patients with metastatic adrenocortical carcinoma: A population-based study 47
Predictors of survival outcomes in patients with neuroendocrine neoplasms: a real-world retrospective study 30
Ambient air pollution and survival in SCLC/LCNEC: Analysis of a single centre retrospective cohort 22
Case Report: Pathologic complete response in triple negative breast cancer treated with anthracycline free regimen 18
The role of 2-[18F]FDG PET/CT in adrenocortical carcinoma: a systematic review 17
Chemo-immunotherapy with cisplatin and nivolumab as second-line approach in metastatic adrenocortical carcinoma 17
Prognostic role of pretreatment [18F]FDG PET/CT in patients affected by adrenocortical carcinoma and treated with chemotherapy 17
Oligometastatic adrenocortical carcinoma: definition and treatment 17
Pharmacological WEE1 inhibition as a strategy to overcome cisplatin resistance in non-seminoma testicular cancer: insights from preclinical models 15
Preclinical evaluation of progesterone combined with EDP-M scheme in 2D and 3D models of adrenocortical carcinoma 10
Primary Adrenal Malignancies 10
Efficacy of RET inhibitors in the management of advanced, RET mutated, pheochromocytoma. Pooled analysis of published cases with the addition of 2 new cases 7
Quality of life questionnaire development and validation for adrenocortical carcinoma patients 6
Current clinical management and outcome of patients with adrenal cortical carcinoma (ACC) with rare histological subtypes-an ENSAT cohort study 4
Totale 10.249
Salva come PNG Salva come JPEG
Categoria #
all - tutte 44.841
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 44.841
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021193 0 0 0 0 0 0 0 0 0 88 38 67
2021/2022398 37 10 12 76 19 27 15 20 17 55 31 79
2022/2023440 50 22 27 31 36 96 4 48 56 16 29 25
2023/2024918 43 31 74 75 74 171 27 50 129 61 23 160
2024/20252.833 54 45 30 414 174 131 154 88 293 122 675 653
2025/20264.062 343 507 570 484 392 331 562 191 326 356 0 0
Totale 10.249